New hope for blood cancer patients: experimental combo aims to wipe out leukemia more effectively
NCT ID NCT07228273
Summary
This study is testing whether adding a targeted drug called venetoclax to a specific chemotherapy regimen works better than standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). Researchers will compare two treatment approaches in about 102 participants to see which one more effectively eliminates cancer cells and leads to longer remission. The goal is to control the disease and prepare eligible patients for a potential stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.